Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical ScreeningReportar como inadecuado




Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

We aimed to determine the disagreement in primary cervical screening between four human papillomavirus assays: Hybrid Capture 2, cobas, CLART, and APTIMA. Material from 5,064 SurePath samples of women participating in routine cervical screening in Copenhagen, Denmark, was tested with the four assays. Positive agreement between the assays was measured as the conditional probability that the results of all compared assays were positive given that at least one assay returned a positive result. Of all 5,064 samples, 1,679 33.2% tested positive on at least one of the assays. Among these, 41% tested positive on all four. Agreement was lower in women aged ≥30 years 30%, vs. 49% at <30 years, in primary screening samples 29%, vs. 38% in follow-up samples, and in women with concurrent normal cytology 22%, vs. 68% with abnormal cytology. Among primary screening samples from women aged 30–65 years n = 2,881, 23% tested positive on at least one assay, and 42 to 58% of these showed positive agreement on any compared pair of the assays. While 4% of primary screening samples showed abnormal cytology, 6 to 10% were discordant on any pair of assays. A literature review corroborated our findings of considerable disagreement between human papillomavirus assays. This suggested that the extent of disagreement in primary screening is neither population- nor storage media-specific, leaving assay design differences as the most probable cause. The substantially different selection of women testing positive on the various human papillomavirus assays represents an unexpected challenge for the choice of an assay in primary cervical screening, and for follow up of in particular HPV positive-cytology normal women.



Autor: Matejka Rebolj , Sarah Preisler , Ditte Møller Ejegod, Carsten Rygaard, Elsebeth Lynge, Jesper Bonde

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados